Addition of Formoterol or Montelukast to Low-Dose Budesonide: An Efficacy Comparison in Short- and Long-Term Asthma Control

Respiration ◽  
2004 ◽  
Vol 71 (6) ◽  
pp. 594-601 ◽  
Author(s):  
Erkan Ceylan ◽  
Mehmet Gencer ◽  
Sahin Aksoy
2019 ◽  
Vol 31 (4) ◽  
pp. e12692 ◽  
Author(s):  
Antonio Bianchi ◽  
Antonella Giampietro ◽  
Linda Tartaglione ◽  
Sabrina Chiloiro ◽  
Raffaella Gentilella ◽  
...  

CHEST Journal ◽  
2000 ◽  
Vol 117 (2) ◽  
pp. 440-446 ◽  
Author(s):  
Antonio Foresi ◽  
Maria Cristina Morelli ◽  
Ernesto Catena
Keyword(s):  

Renal Failure ◽  
2011 ◽  
Vol 33 (3) ◽  
pp. 298-306 ◽  
Author(s):  
Masaru Nakayama ◽  
Kensuke Izumaru ◽  
Masaharu Nagata ◽  
Hirofumi Ikeda ◽  
Kanako Nishida ◽  
...  

2010 ◽  
Vol 3 (3) ◽  
pp. 90-93 ◽  
Author(s):  
Renee Bittoun ◽  
Giuseppe Femia

Managing smoking cessation during pregnancy is vital to the wellbeing of the fetus and the mother. Women who continue to smoke during pregnancy expose the fetus to thousands of chemicals which have been shown to cause deleterious short- and long-term effects. Although a large majority of women cease smoking early in the pregnancy, many of them relapse following delivery. Following a review of current research, an overview of the safety and efficacy of smoking cessation treatments for pregnant women will be considered. Limited research has been performed in this field; however, it can be concluded that low-dose intermittent nicotine replacement therapy is a safe treatment modality for women who smoke during pregnancy. At present there has been no research on other current smoking cessation treatments; however, we will suggest techniques to improve cessation rates and strategies to reduce relapse.


1997 ◽  
Vol 93 (5) ◽  
pp. 443-449 ◽  
Author(s):  
S. Fushiki ◽  
Yasuko Hyodo-Taguchi ◽  
Chikako Kinoshita ◽  
Yuji Ishikawa ◽  
Tomohisa Hirobe

2020 ◽  
Vol 10 (1) ◽  
pp. 170-174
Author(s):  
Sardar Q. Umer ◽  
Tariq W. Sadeq

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances; the clinical presentation dominated by manifestations of hyperandrogenism, which generates short- and long-term consequences on female health sterility, infertility is one of the most alarming associated morbidities. Forty women (28.9 ± 0.8 years old) with polycystic ovarian syndrome had infertility and there were enrolled in these clinical trials and randomly allocated into two groups. Group one and Group two were given treated infertility drugs (Clomid 5 mg for 5 days) and recombinant follicle-stimulating hormone (rFSH) 75 IU for long and short duration to get pregnant. Serum testosterone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) of both groups were measured when women diagnosed as PCOS. The results showed that women which treated by low-dose recombinant FSH 75 IU for 3 days consequently (Group one) have significant decreased LH, while progesterone and FSH significantly increased after treated by hormone therapy P ≥ 0.05 while after treatment with recombinant FSH IU for 5 days (Group two), the result showed non-significant effect as compared with the first group. Concluded: Increase pregnant rate and decrease over stimulation syndrome among infertile women associated with polycystic overian syndrome, when treated with applicated low dose and short term by rFSH hormone.


2002 ◽  
Vol 36 (12) ◽  
pp. 1944-1949 ◽  
Author(s):  
Catherine A Heyneman ◽  
Rachel Crafts ◽  
Jerry Holland ◽  
Aaron D Arnold

OBJECTIVE: To evaluate the relative clinical superiority of increasing the dose of fluticasone propionate versus the addition of salmeterol to low-dose fluticasone propionate for long-term asthma control. DATA SOURCES: Literature was identified by a MEDLINE search (1966–October 2002). Key search terms included asthma, inhalation, corticosteroid, β-adrenergic agonist, and combination drug therapy. DATA SYNTHESIS: Current guidelines for long-term control of asthma include treatment with either inhaled corticosteroids (medium dose) or inhaled corticosteroids (low to medium dose) in combination with a long-acting bronchodilator. Previous studies evaluating salmeterol or formoterol combination therapy with beclomethasone or budesonide have generally produced superior results compared with increasing the dose of the inhaled corticosteroid. Four recent controlled clinical trials have compared the clinical utility of fluticasone propionate monotherapy versus salmeterol/low-dose fluticasone propionate for long-term asthma control in patients with moderate to severe persistent asthma. Based on spirometry data, rescue albuterol use, and symptom scores, the addition of salmeterol to low-dose fluticasone propionate was superior to increasing the dose of fluticasone propionate. CONCLUSIONS: Based on improvements in forced expiratory volume in 1 second, peak expiratory flow, and symptom control, the addition of salmeterol to low-dose fluticasone propionate provides better control of asthma than increasing the dose of fluticasone propionate.


Sign in / Sign up

Export Citation Format

Share Document